Author: Louis Navellier and the InvestorPlace Research Staff

In short, it has significant long-term growth potential and looks set for a recovery.

You can take advantage of its dip or wait for signs of a rally, but its long-term growth picture looks pretty convincing.

Despite its recent slump, with four straight quarters of earnings beats and strong performance, it has long-term growth potential.

These names are the next generation of biotechs that will influence 21st Century medicine.

Thanks to its high quality, reasonable valuation and still-strong prospects, it remains a name to hold for the long haul.